189 related articles for article (PubMed ID: 32592868)
1. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
Bose RJC; McCarthy JR
Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
[No Abstract] [Full Text] [Related]
2. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
Pang X; Cui Y; Zhu Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
[No Abstract] [Full Text] [Related]
3. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
Sanchis-Gomar F; Lavie CJ; Morin DP; Perez-Quilis C; Laukkanen JA; Perez MV
Am J Cardiovasc Drugs; 2020 Oct; 20(5):413-418. PubMed ID: 32737841
[TBL] [Abstract][Full Text] [Related]
4. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
5. Does Ibuprofen Worsen COVID-19?
Moore N; Carleton B; Blin P; Bosco-Levy P; Droz C
Drug Saf; 2020 Jul; 43(7):611-614. PubMed ID: 32529474
[No Abstract] [Full Text] [Related]
6. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
7. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
8. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
[TBL] [Abstract][Full Text] [Related]
9. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
[TBL] [Abstract][Full Text] [Related]
10. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
11. Why is SARS-CoV-2 infection milder among children?
Palmeira P; Barbuto JAM; Silva CAA; Carneiro-Sampaio M
Clinics (Sao Paulo); 2020; 75():e1947. PubMed ID: 32428111
[No Abstract] [Full Text] [Related]
12. SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.
Cao Z; Wu Y; Faucon E; Sabatier JM
Infect Disord Drug Targets; 2020; 20(3):348-349. PubMed ID: 32370727
[No Abstract] [Full Text] [Related]
13. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
15. Does SARS-CoV-2 infection cause sperm DNA fragmentation? Possible link with oxidative stress.
Sengupta P; Dutta S
Eur J Contracept Reprod Health Care; 2020 Oct; 25(5):405-406. PubMed ID: 32643968
[No Abstract] [Full Text] [Related]
16. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
Brogi S; Calderone V
Br J Clin Pharmacol; 2020 Jun; 86(6):1178-1179. PubMed ID: 32359080
[No Abstract] [Full Text] [Related]
17. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
18. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
Dabaghian F; Khanavi M; Zarshenas MM
Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
[No Abstract] [Full Text] [Related]
19. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
20. Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis.
Grace JA; Casey S; Burrell LM; Angus PW
Hepatol Int; 2020 Sep; 14(5):884-885. PubMed ID: 32886332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
